LGND - リガンド・ファ―マシュ―ティカルズ （Ligand Pharmaceuticals Incorporated） リガンド・ファ―マシュ―ティカルズLGNDのチャート
LGNDの企業情報
| symbol | LGND |
|---|---|
| 会社名 | Ligand Pharmaceuticals Inc （リガンド・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 リガンド・ファーマシューティカルズ(Ligand Pharmaceuticals Incorporated)は製薬企業が医薬品を発見・開発するのを助ける技術の開発と獲得に重点を置くバイオ医薬品会社である。同社はバイオ医薬品資産の開発およびライセンス供与に関与する。同社は核内受容体アッセイ、ハイスループットコンピュータスクリーニング、製剤科学、肝臓標的化プロドラッグ技術、抗体発見技術などの研究技術を使用して、処方箋医薬品承認を取得するための企業を支援する。同社は、85社以上の製薬会社およびバイオテクノロジー企業とパートナーシップおよびライセンス契約を結んで、ライセンスを受けている140以上の多数のプログラムが、商業化および開発のさまざまな段階にある。同社は癌、骨粗しょう症、真菌感染症および低血小板を治療する承認された医薬品の研究と技術開発に従事する。 リガンド・ファ―マシュ―ティカルズは、米国の製薬会社。主な製品は、血小板減少症薬｢プロマクタ｣、多発性骨髄腫治療薬｢カイプロリス｣、骨粗しょう症予防薬｢ビビアント｣と｢コンブリザ｣、統合失調症治療薬｢ジオドン｣など。本社は、カリフォルニア州ラホヤ。 Ligand Pharmaceuticals is a biopharmaceutical company located in San Diego, California. Founded in 1987 as Progenx Inc., the company went public in 1992. |
| 本社所在地 | 11119 North Torrey Pines Rd Suite 200 La Jolla CA 92037 USA |
| 代表者氏名 | Matthew W. Foehr Matthew W. Foehr |
| 代表者役職名 | President Chief Operating Officer 社長兼最高執行責任者（COO） |
| 電話番号 | +1 858-550-7500 |
| 設立年月日 | 32021 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 19人 |
| url | www.ligand.com |
| nasdaq_url | https://www.nasdaq.com/symbol/lgnd |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 165.34200 |
| 終値（lastsale） | 247.225 |
| 時価総額（marketcap） | 5217397091.225 |
| 時価総額 | 時価総額（百万ドル） 3957.392 |
| 売上高 | 売上高（百万ドル） 230.03900 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 3746.951 |
| 当期純利益 | 当期純利益（百万ドル） 152.25500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Ligand Pharmaceuticals Inc. revenues increased from $57.3M to $146.2M. Net income increased from $11.1M to $118.4M. Revenues reflect Revenue Sales of Goods_Services increase from $12.2M to $82M Royalty Rights increase of 36% to $52.2M Material sales increase of 80% to $12M. Net income benefited from Gain (Loss) from Viking increase from $2.5M (expense) to $61.1M (income). |
LGNDのテクニカル分析
LGNDのニュース
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) – Analysts’ Revisions Show An Improving Sentiment 2023/01/02 21:00:00 Stocks Register
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) traded at $66.80 at close of the session on Friday, 12/30/22, made a downward move of -1.17% on its previous day’s price. Looking at the stock we see that its previous close was $67.59 and the beta (5Y monthly) reads 1.07 with the day’s price range being $65.57 – $67.425. In … Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) – Analysts’ Revisions Show An Improving Sentiment Read More »
A New Ligand Is Taking Shape (NASDAQ:LGND) 2022/12/30 14:06:37 Seeking Alpha
Ligand''s spinoff of OmniAb has rightsized Ligand as it faces revenue challenges. Click here to learn why I''m neutral on LGND stock at the current price.
Ligand Pharma PT Raised to $90 at Roth Capital 2022/12/27 10:21:01 Investing.com
https://www.investing.com/news/pro/ligand-pharma-pt-raised-to-90-at-roth-capital-432SI-2970362
Ligand Pharma Issues Mixed Guidance For FY23 2022/12/13 19:47:26 Benzinga
At its Investor and Analyst Day event, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND ) provided an overview of Ligand''s corporate structure and business following the successful spin-off of its OmniAb antibody discovery business. Management also introduced 2023 financial guidance . Related: Ligand To Spin-Off OmniAb Via Avista Capital-Backed SPAC Merger . The … Full story available on Benzinga.com
Ligand Pharma PT Raised to $65 at JPMorgan 2022/12/06 12:16:02 Investing.com
https://www.investing.com/news/pro/ligand-pharma-pt-raised-to-65-at-jpmorgan-432SI-2958221
Ligand Pharma PT Raised to $65 at JPMorgan 2022/12/06 12:16:02 Investing.com
https://www.investing.com/news/pro/ligand-pharma-pt-raised-to-65-at-jpmorgan-432SI-2958221
Ligand Pharmaceuticals (LGND) Investor Presentation - Slideshow (NASDAQ:LGND) 2022/12/02 14:22:24 Seeking Alpha
The following slide deck was published by Ligand Pharmaceuticals Incorporated in conjunction with this event.
Ligand Pharmaceuticals, Inc. (LGND) Q3 2022 - Earnings Call Transcript 2022/11/08 02:50:12 Seeking Alpha
Ligand Pharmaceuticals, Inc. (NASDAQ:NASDAQ:LGND) Q3 2022 Earnings Conference Call November 07, 2022, 04:30 PM ET Company Participants Simon Latimer - Head, IR John Higgins - CEO Matthew…
Ligand Pharmaceuticals Inc Q3 Profit Decreases, but beats estimates 2022/11/07 22:28:00 Finanz Nachrichten
WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc (LGND) announced earnings for third quarter that decreased from last year but beat the Street estimates.The company''s bottom line came in at $0.40…
Ligand Pharmaceuticals Non-GAAP EPS of $0.41 misses by $0.02, revenue of $66.09M beats by $27.76M (NASDAQ:LGND) 2022/11/07 21:25:50 Seeking Alpha
Ligand Pharmaceuticals press release (LGND): Q3 Non-GAAP EPS of $0.41 misses by $0.02.Revenue of $66.09M (-4.0% Y/Y) beats by $27.76M.Ligand repurchased $38.6 million in…
Ligand Pharmaceuticals: Struggling Along (NASDAQ:LGND) 2022/09/25 13:23:19 Seeking Alpha
Ligand Pharmaceuticals (LGND) is an intriguing but complicated business. Read why there is uncertainty about potential appeal despite a pullback in the shares.
Ligand Pharma PT Lowered to $175 at Roth Capital 2022/09/02 13:10:03 Investing.com
https://www.investing.com/news/pro/ligand-pharma-pt-lowered-to-175-at-roth-capital-432SI-2885151
Ligand Pharmaceuticals Incorporated: Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma 2022/08/24 21:04:00 Finanz Nachrichten
First European Commission approval of a bispecific antibody discovered using OmniAb OmniAb, Inc. is eligible to receive a $10 million milestone upon first commercial sale in Europe Ligand Pharmace…
Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma 2022/08/24 21:00:00 Wallstreet:Online
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that the Janssen Biotech, Inc. (Janssen) received conditional marketing authorization (CMA) from the European Commission for TECVAYLI (teclistamab) as monotherapy for the treatment of patients with relapsed or refractory (R/R) multiple myeloma. Teclistamab is a T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen
Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma 2022/08/24 21:00:00 Business Wire
EMERYVILLE, Calif.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that the Janssen Biotech, Inc. (Janssen) received conditional marketing authorization (CMA) from the European Commission for TECVAYLI® (teclistamab) as monotherapy for the treatment of patients with relapsed or refractory (R/R) multiple myeloma. Teclistamab is a T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 that was discovered by Janssen scientists